Does Buspirone Cause Drowsiness?
Buspirone has a complex and somewhat paradoxical relationship with drowsiness—while it can cause drowsiness and fatigue as reported side effects, it is generally considered less sedating than benzodiazepines and may even have stimulant properties in some patients.
Side Effect Profile from FDA Labeling and Clinical Trials
The FDA drug label for buspirone clearly documents drowsiness as a common adverse effect 1. In controlled clinical trials comparing buspirone to placebo:
- Drowsiness occurred in 10% of buspirone-treated patients versus 9% on placebo 1—a minimal difference that was not statistically significant
- The more prominent CNS effects were dizziness (12% vs 3%), nervousness (5% vs 1%), and lightheadedness (3% vs 0%) 1
- Approximately 3.4% of patients discontinued buspirone due to CNS disturbances, including drowsiness 1
The FDA label explicitly warns that buspirone's CNS effects are unpredictable in individual patients and cautions against operating automobiles or complex machinery until patients know how the drug affects them 1.
Comparative Sedation: Less Than Benzodiazepines
Multiple guidelines and research studies consistently demonstrate that buspirone is significantly less sedating than benzodiazepines:
- In Alzheimer's disease management guidelines, buspirone is listed as a nonbenzodiazepine anxiolytic option, implicitly distinguishing it from the sedating benzodiazepine class 2
- A pooled analysis of 367 female patients showed that diazepam caused significantly more drowsiness, weakness, and fatigue than buspirone 3
- Research directly comparing buspirone to lorazepam found that buspirone caused subjective drowsiness and fatigue but failed to impair objective psychomotor performance, while lorazepam impaired skills objectively 4
The Paradox: Potential Stimulant Properties
Intriguingly, buspirone may actually have stimulant rather than sedative effects in some patients:
- A sleep laboratory study in insomniacs found that buspirone 10 mg at bedtime increased wake time after sleep onset, particularly on the first night of administration 5
- The study concluded that "these data not only confirm that buspirone lacks sedative effects but also suggest that the drug may have stimulant properties" 5
- The authors noted buspirone has "limited usefulness in anxious patients with concomitant sleep difficulties" 5
- In alpha-1 antitrypsin deficiency management, buspirone is specifically recommended for panic disorders at high doses, noting it is "particularly effective" for anxiety—not for sedation 6
Recent Safety Data
A 2026 pharmacovigilance analysis of 1,744 buspirone adverse event reports from the FAERS database found:
- Dizziness (n=141) was the most common adverse event, followed by anxiety (n=133) 7
- Drowsiness was not among the top reported adverse events 7
- A 2024 meta-analysis confirmed higher rates of dizziness (OR=4.66) but did not identify drowsiness as a significant side effect compared to placebo 8
Clinical Context and Practical Implications
When prescribing buspirone, inform patients:
- Drowsiness can occur but is unpredictable—some patients experience fatigue while others may feel more alert or even stimulated
- The effect is generally much less than benzodiazepines and does not typically cause objective performance impairment
- Avoid driving or operating machinery initially until individual response is known 1
- Dizziness and lightheadedness are more common than drowsiness and may be more problematic
- Do not expect sedation—buspirone is not appropriate for patients specifically seeking sleep aid or immediate sedation
Buspirone does not interact with alcohol to worsen sedation (unlike benzodiazepines), though concomitant use should still be avoided 1, 4.
In specific populations, such as gastroparesis patients, the 2025 AGA guidelines suggest against buspirone as first-line treatment but note it may help with early satiety and bloating—sedation is not mentioned as a limiting factor 9.